What is suPARnostic®?
suPARnostic® is a Risk Status Marker, providing additional information regarding the patient, thus acting as a master alarm for a patient’s risk status – an elevated suPARnostic® level reflects a developing critical condition. suPAR is measured by the suPARnostic® ELISA assay developed by ViroGates.
The suPARnostic® ELISA Assay
By measuring an individual’s suPARnostic® level, the prognosis can be supported, the need for therapy is indicated and the effect of treatment can be monitored.
We have worked for several years on the measurement of patient samples with suPARnostic® in a number of disease indications. In several studies, some funded and conducted independent of ViroGates, results have led to the conclusion that an elevated suPARnostic® level carries negative prognostic value of patient survival amongst those suffering from some type of infection and/or inflammatory condition - an information that might be crucial for the doctor in clinical decision-making. For the moment, these findings extend to HIV, TB, Malaria, Sepsis, bacterial and viral CNS infections, Rheumatoid Arthritis, Multiple Sclerosis, and certain cancers.
Performing the suPARnostic® ELISA involves two antibodies with high specificity for suPAR. The plasma sample with an unknown amount of suPAR is immobilized on the microwells on the clear microtiter plate and a detection antibody form a complex with suPAR.
Between each step the plate is washed with wash buffer to remove any proteins that are not specifically bound. After the final wash step the plate is developed by adding the TMB substrate to produce a visible signal (color change from blue to yellow as illustrated on figure 1), which indicates the quantity of suPAR in the sample. The measured absorbance can, based on the values from the standard curve, be converted to the concentration (ng/mL) of suPAR in the sample.
The suPARnostic® ELISA assay utilizes monoclonal mouse and rat antibodies against human suPAR. Monoclonal antibodies are, in contrast to polyclonal antibodies, immunochemically identical and they only react with a specific sequence on suPAR against which they are raised.
The advantages of using monoclonal antibodies compared to using polyclonal antibodies includes: High homogeneity, absence of nonspecific antibodies and no batch-to-batch or lot-to-lot variability. This results in a very robust and reliable assay:
The suPARnostic® ELISA assay measures suPAR in human plasma.
For more information about how suPARnostic® works, please look under
Products - Technology
For more information about suPARnostic® Product Line, please look under
Products - Product Line
For more information on documentation, please look under
Documentation - Publications
